Announcements Trials
Browse Landscape

Status

No longer available 1Approved for marketing 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 11Observational 2Expanded_access 2

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 1CNS 1

Conditions

Glioma 1Gastrointestinal Stromal Tumors 1GIST 1

Interventions

nilotinib 5dabrafenib 4Nivolumab 4Afatinib 4trametinib 3regorafenib 3midostaurin 3elotuzumab 3TIC10 compound 3Sunitinib 3Prednisone 3Capecitabine 3Abiraterone Acetate 33-Iodobenzylguanidine 3venetoclax 2tucatinib 2tempol 2tazemetostat 2talquetamab 2talimogene laherparepvec 2ruxolitinib 2pomalidomide 2olaparib 2niraparib 2leronlimab 2lenvatinib 2ibrutinib 2gilteritinib 2ceritinib 2brexucabtagene autoleucel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × avapritinib × Clear all
NCT04714086 2024-10-24

Expanded Access Program for Avapritinib

Blueprint Medicines Corporation

No longer available
CNSGastrointestinalSarcoma

Glioma, Gastrointestinal Stromal Tumors

NCT03862885 2020-07-27

Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST

Blueprint Medicines Corporation

Approved for marketing
Sarcoma

GIST

Data powered by HemOnc (CC BY 4.0) Colophon âš¡